MOTOR NEURON DISEASE

Ultrasound success removes barriers to targeted drug delivery in amyotrophic lateral sclerosis

Magnetic resonance-guided focused ultrasound (MRgFUS) can be used to transiently and focally permeabilize the blood–brain barrier (BBB), thereby enabling targeted delivery of therapeutic agents into specific brain regions. In a new study, researchers demonstrated that MRgFUS safely and reversibly permeabilized the BBB in eloquent primary motor cortex in four patients with amyotrophic lateral sclerosis (ALS). Opening of the BBB was confirmed by MRI detection of gadolinium leakage into the parenchyma at the target site. Previous studies have shown that MRgFUS can be used in humans to safely open the BBB in non-eloquent areas of cortex, but the new study indicates that the approach could be extended to eloquent cortex. In ALS, therapeutics would ideally be targeted specifically to the motor cortex, so this work provides the foundation for combining MRgFUS with therapeutic agents for targeted drug delivery in the condition.

References

Original article

  1. Abrahao, A. et al. First-in-human trial of blood–brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound. Nat. Commun. 10, 4373 (2019)

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ian Fyfe.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fyfe, I. Ultrasound success removes barriers to targeted drug delivery in amyotrophic lateral sclerosis. Nat Rev Neurol 15, 686 (2019). https://doi.org/10.1038/s41582-019-0276-z

Download citation

Search

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing